DXM Group

What they fund

The firm invests in 'technology-driven startups' within the healthcare sector, leveraging the founder's expertise in medical management and digital transformation [1].

Investment thesis

DXM Group operates as a family office led by Prof. Dr. David Matusiewicz, one of Germany’s most prominent voices in digital health, focusing on startups that leverage technology to solve healthcare challenges [1].

• Evidence-Based Innovation — Investments align with the founder’s academic and professional background in medical management, including his role as Dean of Health & Social Affairs and Director of the Institute for Health & Social Affairs (ifgs), suggesting a focus on scientifically grounded ventures [1].
• Deep Industry Integration — Matusiewicz serves as an advisor and supervisory board member in numerous digital health companies, indicating a strategy of active, hands-on involvement beyond capital [1].
• Multi-Founder Ecosystem — The founder’s track record as a multi-founder (e.g., 10xD GmbH, CIBE Center) suggests DXM Group may favor or support founders with serial entrepreneurship experience or those building within a broader innovation ecosystem [1].

Credibility: The firm’s structure and thesis are directly stated on its official website, which details Prof. Matusiewicz’s roles as Dean, Institute Director, and Family Office Founder, alongside his recognition as a leading voice in German digital health [1].

Value add

DXM Group provides deep industry expertise and active involvement, with the founder serving as an advisor and supervisory board member in portfolio companies [1].

Fit verdict: Ideal for founders seeking a highly engaged, expert investor with strong ties to the German healthcare ecosystem.

Founder diligence script:

• How does DXM Group's involvement in my company's supervisory board or advisory role align with my governance preferences?
• What specific medical management or digital health expertise can Prof. Matusiewicz bring to my regulatory or product strategy?
• How does DXM Group's network of 'numerous digital companies' facilitate partnerships or distribution for my startup?

Portfolio focus

Specific portfolio companies are not publicly listed on the provided website. The firm's focus is inferred from the founder's advisory and supervisory board roles in 'numerous digital companies' [1].

Notable investments & exits

• Portfolio Specifics — Unknown — The provided sources do not list specific company names, investment amounts, or exit events for the DXM Group’s portfolio.
• Founder’s Broader Ventures — Prof. Dr. David Matusiewicz is also a co-founder and partner at 10xD GmbH (since 2022), which may represent a parallel entrepreneurial venture or investment vehicle, though its direct relationship to DXM Group investments is not specified [1].

Strategic implications

DXM Group's primary edge is the founder's unique position as a leading academic and industry voice in German digital health, providing unparalleled access to research, talent, and regulatory insight. The main risk is key-person dependency; the firm's strategy and network are inextricably linked to Prof. Matusiewicz's personal involvement and reputation. A signal that would change the read is if DXM Group were to institutionalize its investment process or bring on a dedicated investment team, which would indicate a shift from a founder-led family office to a more scalable, professionalized vehicle.

Where they could go further

DXM Group could formalize its investment thesis into a public 'call for startups' to attract a broader pipeline of evidence-based health tech ventures. The firm could leverage its founder's academic roles at FOM Hochschule to create a dedicated startup incubator or fellowship, deepening its ties to the next generation of health tech founders. DXM Group could publish a brief annual impact report highlighting its portfolio companies' progress, enhancing its reputation and attracting future co-investors or LPs if it ever scales.